GUIDELINES IN DERMATOLOGY

gdkapak

MYCOSIS FUNGOIDES

Dilek Bayramgürler1
Didem Kazan2

1Kocaeli University, Faculty of Medicine, Department of Dermatology, Kocaeli, Türkiye
2İstanbul Arel University, Faculty of Medicine, Department of Dermatology, İstanbul, Türkiye

Bayramgürler D, Kazan D. Mycosis Fungoides. In: Kutlubay Z, editor. Guidelines in Dermatology. 1st ed. Ankara: Türkiye Klinikleri; 2025. p.153-163.

ABSTRACT

Mycosis fungoides is the most commonly seen clinical subtype of primary cutaneous lymphomas. Since its prevalence is low diagnosis and treatment presents a challenge. Therefore, development and implementation of guidelines for mycosis fungoides presents a great challenge. In this section current guidelines to assist with clinical decision-making for the diagnosis, staging and management of

patients with mycosis fungoides have been reviewed.

Keywords: Mycosis fungoides; Primary cutaneous lymphoma; Guideline; Treatment; Diagnosis

Referanslar

  1. Siegel RS, Pandolfino T, Guitart J, Rosen S, Kuzel TM. Primary cutaneous T-cell lymphoma: review and current concepts. J Clin Oncol. 2000;18(15):2908-25. [Crossref]  [PubMed]
  2. European Medicines Agency; Committee for Orphan Medicinal Products. Public summary of opinion on orphan designation, EMA/COMP/60984/2012. Rev 2. Accessed 21 July 2020. [Link]
  3. Väkevä L, Pukkala E, Ranki A. Increased risk of secondary cancers in patients with primary cutaneous T cell lymphoma. J Invest Dermatol 2000;115:62-5. [Crossref]  [PubMed]
  4. Korgavkar K, Xiong M, Weinstock M. Changing incidence trends of cutaneous T-cell lymphoma. JAMA Dermatol. 2013;149(11):1295-1299. [Crossref]  [PubMed]
  5. Olsen E, Vonderheid E, Pimpinelli N, Willemze R, Kim Y, Knobler R. et al. Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007;110:1713-22. [PubMed]
  6. Wilcox RA. Cutaneous T-cell lymphoma: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol. 2016;91(1):151-165. [Crossref]  [PubMed]  [PMC]
  7. Trautinger F, Knobler R, Willemze R, Peris K, Stadler R, Laroche L. et al. EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome. Eur J Cancer. 2006;42(8):1014-30. [Crossref]  [PubMed]
  8. Trautinger F, Eder J, Assaf C, Bagot M, Cozzio A, Dummer R. et al. European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome Update 2017. Eur J Cancer. 2017;77:57-74. [Crossref]  [PubMed]
  9. Latzka J, Assaf C, Bagot M, Cozzio A, Dummer R, Guenova E. et al. EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome Update 2023. Eur J Cancer. 2023;195:113343. [Crossref]  [PubMed]
  10. Jonak C, Tittes J, Brunner PM, Guenova E. Mycosis fungoides and Sézary syndrome. J Dtsch Dermatol Ges. 2021;19(9):1307-1334. [Crossref]  [PubMed]  [PMC]
  11. Horwitz SM, Ansell S, Ai WZ, Barnes J, Barta SK, Brammer J, et al. NCCN Clinical Practice Guidelines in oncology: Primary Cutaneous Lymphomas, Version 1.2024. J Natl Compr Canc Netw. 2025;1-12. [Link]
  12. Agar NS, Wedgeworth E, Crichton S, Mitchell TJ, Cox M, Ferreira S. et al. Survival Outcomes and Prognostic Factors in Mycosis Fungoides/Sézary Syndrome: Validation of the Revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer Staging Proposal. Journal of Clinical Oncology 2010;28(31):4730-4739. [Crossref]  [PubMed]
  13. Scarisbrick JJ, Kim YH, Whittaker SJ, Wood GS, Vermeer MH, Prince HM. et al. Prognostic factors, prognostic indices and staging in mycosis fungoides and Se'zary syndrome: where are we now? Br J Dermatol 2014;170:1226e36. [Crossref]  [PubMed]
  14. Holwick J, Chalmers I, Glasziou P, Greenhalgh T, Heneghan C, Liberati A. et al. 'The 2011 Oxford CEBM levels of evidence (introductory document)'. Oxford centre for evidence-based medicine. Retrieved March 2023. [Link]
  15. Olsen EA, Whittaker S, Kim YH, Duvic M, Prince HM, Lessin SR. et al. Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. J Clin Oncol. 2011;29(18):2598-2607. [Crossref]  [PubMed]  [PMC]
  16. Ibrahim MA, Eltayeb N, Ibrahim MM, Nassar A, Daruish M, El-Zimaity M. et al. Suggested guidelines for the treatment of mycosis fungoides in countries with limited resources. Dermatology Research and Practice. 2023;2023:1360740. [Crossref]  [PubMed]  [PMC]